Table 1 Clinical information for all patients
Variable | Value |
|---|---|
Total patients | 1838 |
Age (years) | 66.4±13.0 (18–99) |
Elderly (≥ 65) | 1103 (60.0) |
Sex—male/female | 365 (19.9)/1473(80.1) |
Disease duration (months) | 151±129 (20-1040) |
Steinbrocker stage I/II/III/IV | 517 (28.2)/407 (22.2)/442 (24.0)/472 (25.6) |
Steinbrocker class I/II/III/IV | 856 (46.5)/729 (39.7)/207 (11.3)/46 (2.5) |
ACPA (U/ml) | 133±307 (0–7690) |
DAS | 2.9±1.2 (0.28–7.9) |
SDAI | 7.3±6.8 (0.01–57.4) |
HAQ | 0.5±1.2 (0–49) |
DMARDs usage | 1607 (87.4) |
MTX usage | 1117 (60.8) |
MTX dose (mg/week) | 7.2±2.3 (1–14) |
PSL usage | 711 (38.7) |
PSL dose (mg/day) | 3.8±2.1 (0–25) |
Biologics/JAK usage | 501 (27.2) |
Comorbidity | |
Hypertension | 619 (33.7) |
Diabetes mellitus | 149 (8.1) |
Respiratory disease | 224 (12.2) |
Cerebrovascular disease | 86 (4.7) |
Cardiovascular disease | 174 (8.0) |
Renal disease | 464 (25.2) |
Malignant tumor | 105 (5.7) |